Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study

BACKGROUND: Although some targeted therapies have been shown to be effective in treating HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study aimed to assess the effectiveness and safety of pyrotinib plu...

Description complète

Détails bibliographiques
Auteurs principaux: Yang, Yaning, Yang, Guangjian, Li, Weihua, Hao, Xuezhi, Zhang, Shuyang, Ai, Xin, Lei, Siyu, Xu, Haiyan, Wang, Yan
Format: Online Article Texte
Langue:English
Publié: John Wiley & Sons Australia, Ltd 2023
Sujets:
Original Articles
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665774/
https://www.ncbi.nlm.nih.gov/pubmed/37740599
http://dx.doi.org/10.1111/1759-7714.15118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665774/
https://www.ncbi.nlm.nih.gov/pubmed/37740599
http://dx.doi.org/10.1111/1759-7714.15118

Documents similaires